Profile data is unavailable for this security.
About the company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
- Revenue in SEK (TTM)0.00
- Net income in SEK-31.16m
- Incorporated2008
- Employees4.00
- LocationIsofol Medical AB (publ)Biotech Center, Arvid Wallgrens Backe 20GOETEBORG 413 46SwedenSWE
- Phone+46 317972280
- Fax+46 317411701
- Websitehttps://isofolmedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biosergen AB | 0.00 | -28.90m | 95.48m | 4.00 | -- | 1.38 | -- | -- | -0.3579 | -0.3579 | 0.00 | 0.2497 | 0.00 | -- | -- | 0.00 | -113.63 | -- | -147.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| AroCell AB (publ) | 44.79m | -56.13m | 96.29m | -- | -- | 0.6288 | -- | 2.15 | -0.2437 | -0.2437 | 0.1944 | 0.6648 | 0.2325 | 5.82 | 5.63 | -- | -29.14 | -29.25 | -31.00 | -31.37 | 1.88 | -9.85 | -125.33 | -231.19 | 5.16 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
| Bio-Works Technologies AB | 43.90m | -56.82m | 100.96m | 38.00 | -- | 2.29 | -- | 2.30 | -1.58 | -1.58 | 1.22 | 1.13 | 0.571 | 1.82 | 5.83 | 1,155,158.00 | -73.91 | -49.14 | -101.72 | -57.90 | 61.10 | 69.88 | -129.44 | -168.30 | 2.79 | -- | 0.00 | -- | 6.23 | 46.24 | -26.41 | -- | 1.95 | -- |
| NextCell Pharma AB | 12.45m | -39.37m | 102.52m | -- | -- | 1.11 | -- | 8.23 | -0.9046 | -0.9046 | 0.286 | 1.28 | 0.1406 | 14.06 | 7.20 | -- | -44.45 | -34.92 | -50.09 | -37.06 | 12.04 | -68.21 | -316.25 | -538.60 | 4.36 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
| Wntresearch AB | 0.00 | -35.82m | 102.63m | 2.00 | -- | 2.52 | -- | -- | -9.19 | -9.19 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -89.47 | -100.71 | -103.70 | -123.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.65 | -- | -- | -- |
| Sprint Bioscience AB | 68.36m | 8.77m | 104.73m | 36.00 | 11.94 | 4.24 | 11.23 | 1.53 | 0.1256 | 0.1256 | 0.9791 | 0.3538 | 1.58 | -- | 11.45 | 2,441,286.00 | 20.29 | -71.22 | 43.20 | -113.71 | 80.06 | 62.75 | 12.83 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| Spago Nanomedical AB (publ) | 1.47m | -35.58m | 106.55m | 12.00 | -- | 2.01 | -- | 72.68 | -0.3129 | -0.3129 | 0.0113 | 0.1525 | 0.0324 | -- | 9.91 | 112,769.20 | -78.60 | -20.19 | -93.27 | -20.97 | -5.25 | -- | -2,426.88 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| StenoCare A/S | 6.19m | -25.35m | 108.11m | 9.00 | -- | 3.20 | -- | 17.47 | -1.13 | -1.13 | 0.2674 | 1.22 | 0.1285 | -- | 2.94 | -- | -52.62 | -28.16 | -70.34 | -35.47 | -- | -- | -409.55 | -371.06 | 1.04 | -5.56 | 0.2362 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -31.16m | 111.12m | 4.00 | -- | 0.9838 | -- | -- | -0.1964 | -0.1964 | 0.00 | 0.6993 | 0.00 | -- | -- | 0.00 | -20.49 | -66.73 | -24.10 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| New Nordic Healthbrands AB | 537.81m | -10.17m | 112.75m | 70.00 | -- | 1.08 | -- | 0.2097 | -1.64 | -1.64 | 86.81 | 16.86 | 2.16 | 1.84 | 4.96 | 7,367,219.00 | -4.09 | 5.36 | -9.16 | 10.55 | 65.32 | 67.30 | -1.89 | 2.38 | 0.8584 | -4.44 | 0.2821 | 47.96 | 9.51 | 6.28 | -119.41 | -- | 28.36 | -- |
| Odi Pharma AB (publ) | 14.80m | -1.67m | 117.19m | -- | -- | 33.59 | -- | 7.92 | -0.1097 | -0.1097 | 0.9727 | 0.2293 | 1.36 | 18.13 | 3.94 | -- | -15.36 | -- | -39.25 | -- | -25.26 | -- | -11.27 | -- | 1.26 | -2.31 | 0.00 | -- | -55.44 | -- | 4.67 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 7.77m | -77.95m | 120.06m | 18.00 | -- | 1.24 | -- | 15.46 | -1.33 | -1.33 | 0.129 | 0.8696 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Coegin Pharma AB | 0.00 | -27.98m | 121.24m | 0.00 | -- | 9.31 | -- | -- | -2.65 | -2.65 | 0.00 | 0.6403 | 0.00 | -- | -- | -- | -125.24 | -122.02 | -201.53 | -154.70 | -- | -- | -- | -28,466.75 | -- | -170.65 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
| Toleranzia AB | 0.00 | -6.30m | 125.73m | 7.00 | -- | 0.8232 | -- | -- | -0.0405 | -0.0405 | 0.00 | 0.775 | 0.00 | -- | -- | 0.00 | -4.50 | -7.45 | -4.65 | -7.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.79 | -- | 63.90 | -- |
| Circa Group AS | 18.49m | -70.94m | 128.89m | 17.00 | -- | 0.3809 | -- | 6.97 | -0.6611 | -0.6611 | 0.1698 | 2.81 | 0.0403 | 5.46 | 0.9139 | 1,104,253.00 | -15.46 | -- | -19.96 | -- | 75.64 | -- | -383.72 | -- | 0.7097 | -- | 0.00 | -- | 41.73 | -- | -0.0491 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Isofol Medical AB (publ)'s reporting currency: Swedish Krona SEK
1.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SEB Investment Management ABas of 31 May 2024 | 1.02m | 0.63% |
| Handelsbanken Fonder ABas of 31 May 2024 | 900.00k | 0.56% |
| FCG Fonder ABas of 31 Dec 2023 | 432.97k | 0.27% |
| Skandia Investment Management ABas of 30 Apr 2024 | 159.45k | 0.10% |
| Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 29 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
